SCHEMBL7177129

SCHEMBL7177129

O[C@H]1CCCc2ccc(OCc3ccncc3)cc21

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.42
RXRA P19793 3/20 0.42
RXRB P28702 3/20 0.42
RXRG P48443 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ESR1 P03372 1/20 0.41
NR3C1 P04150 1/20 0.41
ESR2 Q92731 1/20 0.41
HRH3 Q9Y5N1 4/20 0.41
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CYP2D6 P10635 2/20 0.39
CYP19A1 P11511 4/20 0.39
CYP11B1 P15538 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7176955 1.00 CSF1R (0.42) CSF1RRXRARXRBRXRGNPC1
SCHEMBL7175987 1.00 CSF1R (0.42) CSF1RRXRARXRBRXRGNPC1
SCHEMBL7182343 0.85 ACHE (0.48) CSF1RRXRARXRBRXRGNPC1
SCHEMBL7175494 0.82 RXRA (0.44) CSF1RRXRARXRBRXRGNPC1
SCHEMBL7175491 0.82 RXRA (0.44) CSF1RRXRARXRBRXRGNPC1
SCHEMBL1746574 0.79 HRH3 (0.53) HRH3MAOAMAOBCYP2D6
SCHEMBL8462058 0.78 RXRB (0.61) RXRARXRBRXRGNPC1RAB9A
SCHEMBL7181843 0.77 KDM4E (0.50) HRH3MAOAMAOBCYP2D6
SCHEMBL7623162 0.74 RXRA (0.39) CSF1RRXRARXRBRXRGNPC1
SCHEMBL10682896 0.74 ALOX5AP (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0941112-B1 METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS VERTEX PHARMA (US) 2003-02-12 EP disclosed
EP-0839143-B1 TETRALIN COMPOUNDS WITH MDR ACTIVITY VERTEX PHARMA (US) 2002-08-07 EP disclosed
US-5726184-A TREATMENT OF MULTI-DRUG RESISTANT CELLS TO RESTORE SENSITIVITY TO THERAPEUTIC OR PROPHYLACTIC AGENTS VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-03-10 US disclosed